Company news
BetterLife Pharma Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
BetterLife Pharma Engages Market Maker
November 20, 2026
BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026
November 17, 2026
BetterLife Pharma Announces Stock Option Grant
November 17, 2026
BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha
November 6, 2026
2026-11-05 BETR – Board Changes FINAL
November 5, 2026
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
November 5, 2026
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
October 27, 2026
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
October 19, 2026
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
October 15, 2026
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
October 14, 2026
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
October 9, 2026
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
September 29, 2026
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
September 17, 2026
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
September 11, 2026
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
August 31, 2026
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
August 28, 2026
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
August 24, 2026
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
August 19, 2026
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
July 13, 2026
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
July 9, 2026
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
July 6, 2026
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
June 25, 2026
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
June 22, 2026
Annual Report for Fiscal Year Ending January 31, 2026 (Form 20-F)
June 1, 2026
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
May 13, 2026
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
January 6, 2026
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
December 11, 2025
BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen
December 4, 2025
BetterLife Pharma Highlights Advantages of BETR-001 - a Potent Neuroplastogen
December 4, 2025
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor
November 25, 2025
BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor
October 22, 2025
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent
June 18, 2025
BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
May 28, 2025
BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release
May 22, 2025
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
May 14, 2025
BetterLife Announces Debt Settlements
May 6, 2025
BetterLife Pharma Appoints Corporate Advisor
April 3, 2025
BetterLife Pharma Appoints New Director
March 31, 2025
BetterLife Announces Debt Conversions
March 10, 2025
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 15, 2024
BetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 24, 2023
BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference
October 25, 2021
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
October 18, 2021
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
October 11, 2021
April Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass Adoption
April 28, 2021
Horizons ETFs Completes Rebalance of World's First Psychedelics ETF
March 26, 2021
BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
March 24, 2021
CSE Bulletin: Fundamental Change - BetterLife Pharma Inc. (BETR)
August 31, 2020
BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan
July 27, 2020
BetterLife Pharma Announces Consolidation of its Common Shares
June 24, 2020
Decks
- Investor Presentation (July 2026)
Investor deck · 18 slides · July 2026
- Investor Presentation (January 2023)
Investor deck · 15 slides · Jan 13, 2023
- Investor Presentation (August 2022)
Investor deck · 15 slides · August 2022
- Investor Presentation (December 2021)
Investor deck · 23 slides · December 2021
- Investor Presentation (May 2021)
Investor deck · 27 slides · May 26, 2021